ACHV — Achieve Life Sciences Income Statement
0.000.00%
Last trade - 00:00
- $157.90m
- $159.02m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.5 | 14.8 | 33.1 | 40.8 | 27.3 |
Operating Profit | -16.5 | -14.8 | -33.1 | -40.8 | -27.3 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.4 | -14.7 | -33.2 | -42.4 | -29.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.4 | -14.7 | -33.2 | -42.4 | -29.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.4 | -14.7 | -33.2 | -42.4 | -29.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.4 | -14.7 | -33.2 | -42.4 | -29.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -39.8 | -5.42 | -4.08 | -4 | -1.5 |